title: [A cross-sectional study of factors related to traditional Chinese medicine use for hospitalized acute coronary syndrome patients in China's level 2 hospitals].
abstract: OBJECTIVE
  To explore the current status on traditional Chinese medicine (TCM) use for hospitalized acute coronary syndrome patients in China's level 2 hospitals, and to explore associated factors of TCM use for these patients.
  
  
  METHODS
  This survey was performed in 102 level 2 hospitals from 15 provinces or autonomous region in China. Patients admitted to these hospitals with acute coronary syndrome during September 2011 to May 2012 were eligible for this study. Information on TCM use was obtained from their medical records. Chi-square test and logistic regression analysis were used to explore the related factors of TCM use in these patients.
  
  
  RESULTS
  We recruited 5 432 acute coronary syndrome patients in this study, TCM was applied to 3 503 patients (64.5%). Multivariable logistic regression showed that pre-hospital TCM use was positively related with in-hospital TCM use (OR = 2.08, P < 0.01) , while pre-hospital use of 4 medicines recommended by the guidelines(including aspirin/clopidogrel, β acceptor blocker, stain and angiotensin converting enzyme inhibitor/angiotensin converting enzyme receptor blocker ), being a smoker and diagnosis of myocardial infarction rather than unstable angina at hospital discharge were negatively related with in-hospital TCM use (the ORs were 0.58, 0.78 and 0.71, respectively, all P < 0.01). The TCM use varied significantly between regions. Taking southwest region as a reference, the ORs varied between 2.98-13.37 (all P < 0.01) in eastern China, south China, central China, north China, northwest and northeast regions.
  
  
  CONCLUSIONS
  TCM is widely used in hospitalized acute coronary syndrome patients in China's resource-constrained level 2 hospitals. Pre-hospital TCM use is positively correlated with in-hospital TCM use for these patients.
authors.affiliation: School of Public Health, Peking University Health Science Centre, Beijing 100191, China.
authors.forename: Yifei
authors.initials: Y
authors.lastname: Zhao
authors.forename: Shenshen
authors.initials: S
authors.lastname: Li
authors.forename: Lihong
authors.initials: L
authors.lastname: Ma
authors.forename: Yihong
authors.initials: Y
authors.lastname: Sun
authors.forename: Xin
authors.initials: X
authors.lastname: Du
authors.forename: Yong
authors.initials: Y
authors.lastname: Huo
authors.forename: Dayi
authors.initials: D
authors.lastname: Hu
authors.forename: Runlin
authors.initials: R
authors.lastname: Gao
authors.affiliation: Email: ywu@georgeinstitute.org.cn.
authors.forename: Yangfeng
authors.initials: Y
authors.lastname: Wu
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000368:Aged; D002681:China; D003430:Cross-Sectional Studies; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007297:Inpatients; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D004365:Drugs, Chinese Herbal